| Metric | Value (₹ Cr) | vs Q2 FY25 |
|---|---|---|
| Revenue | 14.46 | 9.9% |
| Total Income | 14.52 | 10.3% |
| Expenditure | 11.50 | 10.7% |
| PBT | 3.02 | 8.8% |
| Net Profit | 2.49 | 24.3% |
| OPM | 17.98% | |
| NPM | 17.15% | 1.93pp |
| EPS | 2.53 | 24.0% |
Astal Laboratories Limited Delivers Robust Quarter 3, FY 2024-25 Performance & Future Outlook
31 Jan 2025 · 31 Jan 2025, 06:06 pm
Summary
Astal Laboratories Limited, a prominent player in the Active Pharmaceutical Ingredients (API) and bulk drug manufacturing sector, has announced its unaudited financial results for the quarter and nine months ended December 31, 2024. The results reflect significant growth in revenue and profitability, with the Q3 FY 2024-25 revenue from operations increasing by 71.9% YoY to INR 1,445.88 Lakhs.
Key Highlights
- 1
Q3 FY 2024-25 revenue from operations increased by 71.9% YoY
- 2
Total revenue for the quarter stood at INR 1,451.47 Lakhs, a 72.5% YoY increase
- 3
Profit Before Tax (PBT) rose to INR 301.79 Lakhs, a 519% YoY growth
- 4
Profit After Tax (PAT) for the quarter reached INR 248.86 Lakhs, a 410% YoY increase
- 5
9-Month PAT grew to INR 618.05 Lakhs, a 1,072% YoY increase
Management Comments
Mr. Sudheer Karna Kankanala
The Q3 results reflect our commitment to growth and operational excellence. We have achieved strong financial performance this quarter, driven by our focus on innovation, efficiency, and market expansion. As we move forward, we remain dedicated to delivering value to our stakeholders and strengthening our position in the API and bulk drug manufacturing space.
Informational and educational content only. Not investment advice.